Clear.bio, an Amsterdam-based healthtech company, recently captured the spotlight by raising €1.7 million in its latest funding round. Known for its innovative approach in personalized diabetes care, the startup anticipates using this fresh capital to widen the reach of its digital diabetes remission program within the Netherlands and to secure reimbursement from health insurers in France and Germany. The demand for effective diabetes management has increased the company’s focus on expanding its offerings internationally.
A few years ago, in 2022, Clear.bio raised funds from the Achmea Innovation Fund, highlighting its consistent journey toward growth. The company’s 2025 registration as a Class I medical device under European MDR confirms Clear.bio’s adherence to high medical standards. Over the years, the focus has always been on utilizing technology to manage, rather than just treat, type 2 diabetes effectively, addressing the growing health challenges across Europe.
What Drives Clear.bio’s Ambition?
The recent funding comes from prominent investors such as Horizon Flevoland, Future Food Fund, Invest International’s Dutch Trade & Investment Fund, along with individual business angels. Clear.bio’s mission revolves around empowering individuals with diabetes to better manage their health. The founder, Piet Hein van Dam, reinforced this sentiment by stating:
“This investment allows us to empower more individuals to take charge of their health and expand our proven solution internationally.”
The company envisions reaching the 70 million diabetes patients in Europe, offering them a chance to minimize reliance on medication.
How is Clear.bio Innovating Diabetes Care?
Clear.bio, co-founded by Madelon Bracke and Piet Hein van Dam in 2019, offers a digital platform that personalizes care through custom diet plans. Recently, they’ve introduced features like ‘Smart Swap’ and ‘Smart Signal,’ innovative tools that analyze individual glucose data to provide real-time advice. This evolution from manual dietitian input to automated, data-driven guidance represents a significant shift.
The new Smart Swap offers personalized dietary suggestions, while Smart Signal sends alerts when unusual glucose patterns are detected. An example notification might read:
“Your blood sugar is rising quickly – consider going for a walk.”
These automated features enhance the app’s functionality, providing users with immediate, actionable insights into their health.
Clear.bio’s initiatives are crucial as type 2 diabetes continues to rise, with expensive medications only managing, not curing, the disease. By supplementing traditional medication with digital health solutions, the company aims to engender a paradigm shift in managing diabetes on a broader scale.
Clear.bio’s integration of digital technology and healthcare demonstrates a challenging yet promising direction for diabetes management. By prioritizing personalization and real-time feedback, it could significantly influence how patients navigate their health journeys. The long-term sustainability and effectiveness of such solutions will depend on continuous innovations and strategic collaborations. For individuals managing diabetes, understanding the integration of digital solutions into their daily healthcare routine can provide substantial benefits and a proactive approach to managing their well-being.
